Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relapsed and/or Refractory Multiple Myeloma (RRMM) Clear all
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 10:57 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Teclistamab Monotherapy, Teclistamab
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced May 21, 2026, 10:57 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Multiple Myeloma, Renal Impairment
Interventions
4 mg Oral POM + 40 mg Oral DEX, 2 mg Oral POM + 40 mg Oral DEX
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Denver, Colorado • Atlanta, Georgia • Harvey, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced May 21, 2026, 10:57 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
35
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fort Collins, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced May 21, 2026, 10:57 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidity
Interventions
Isatuximab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 10:57 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Daratumumab, Dexamethasone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Anaheim, California • Denver, Colorado • Tallahassee, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced May 21, 2026, 10:57 PM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
mRNA-2736
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Birmingham, Alabama • Miami, Florida • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced May 21, 2026, 10:57 PM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
isatuximab SAR650984, Pomalidomide, Dexamethasone, Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
24
States / cities
Little Rock, Arkansas • Fullerton, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced May 21, 2026, 10:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced May 21, 2026, 10:57 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced May 21, 2026, 10:57 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Daratumumab, Bortezomib, Iberdomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
43
States / cities
Hot Springs, Arkansas • Cerritos, California • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 21, 2026, 10:57 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced May 21, 2026, 10:57 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Bortezomib, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
20
States / cities
Plantation, Florida • Atlanta, Georgia • Honolulu, Hawaii + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced May 21, 2026, 10:57 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
isatuximab SAR650984, lenalidomide, dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
5
States / cities
San Francisco, California • Tampa, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced May 21, 2026, 10:57 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cyclophosphamide, Ixazomib, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Hazard, Kentucky • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced May 21, 2026, 10:57 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-79635322
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
29
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 10:57 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Arlocabtagene Autoleucel
Biological
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
41
States / cities
Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced May 21, 2026, 10:57 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
18F-fluciclovine injection, 18F-FDG PET/CT
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 21, 2026, 10:57 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Durvalumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
8
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 21, 2026, 10:57 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced May 21, 2026, 10:57 PM EDT
Suspended Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
Mirdametinib, Sirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 10:57 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melflufen, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Oncopeptides AB
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
14
States / cities
Tucson, Arizona • Fresno, California • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced May 21, 2026, 10:57 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Tucson, Arizona • Beverly Hills, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced May 21, 2026, 10:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Goodyear, Arizona • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced May 21, 2026, 10:57 PM EDT